Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes;Omkostningseffektivitet ved behandling af type 1-diabetes med insulinpumpe Originalartikel

Ugeskrift for Laeger

Volumn 172, Issue 27, 2010, Pages

  Nørgaard, Kirsten ^a,b   Sohlberg, Anna ^a,b  

^a Læge Gordan Goodall Hvidovre Hospital   (Sweden)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ARTICLE; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; LIFE EXPECTANCY; MALE; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; FEMALE; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; LIFE EXPECTANCY; MALE; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 77954945658     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Svensson J, Carstensen B, Mølbak AG et al. Increased risk of childhood type 1 diabetes in children born after 1985. Diab Care 2002;25:2197-2201.
2. Carstensen B, Kristensen JK, Ottosen P et al. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 2008;51:2187-96.
3. Renard E. Intensive insulin therapy today: "basal-bolus" using multiple daily injections or CSII? Diabetes Metab 2005;31:4S40-4.
4. Boland EA, Grey M, Oesterle A et al. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diab Care 1999;22:1779-84.
5. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
6. Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004;47:622-9.
7. Doyle EA, Weinzimer SA, Steffen AT et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diab Care 2004;27:1554-8.
8. Linkeschova R, Raoul M, Bott U et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diab Med 2002;19:746-51.
9. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diab Care 2002;25:593-8.
10. Palmer AJ, Roze S, Valentine WJ et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20:S5-S26.
11. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a meta-analysis. Diab Care 2003;26:1079-87.
12. Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 1995;155:745-54.
13. Eliasson B, Cederholm J, Nilsson P et al. The gap between guidelines and reality: Type 2 diabetes in a National Diabetes Register 1996-2003. Diab Med 2005;22:1420-6.
14. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2008;38:583-637.
15. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705.
16. Bode BW, Sabbah HT, Gross TM et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 2002;18:S14-20.
17. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 2004;8:43.
18. Bruttomesso D, Pianta A, Crazzolara D et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life. Diabet Med 2002;19:628-34.
19. St charles ME, Sadri H, Minshall ME et al. Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada. Clin Ther 2009;31:657-67.
20. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med 2002;111:69-77.
21. Weintrob N, Shalitin S, Phillip M. Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes. Isr Med Assoc J 2004;6:271-5.